Sunshine Biopharma has advanced its lead coronavirus PLpro inhibitor program into IND-enabling studies after preclinical testing demonstrated broad-spectrum antiviral activity against SARS-CoV-2 variants. According to company disclosures, the small-molecule candidate exhibits nanomolar potency against the viral protease and favorable oral bioavailability in animal models.
Preclinical Efficacy and Drug Characteristics
Laboratory evaluations show that the small molecule achieves nanomolar potency against the viral protease and maintains broad-spectrum activity across multiple SARS-CoV-2 variants of concern, according to Sunshine Biopharma data. In pharmacokinetic evaluations, animal models demonstrated favorable absorption, distribution, metabolism, and excretion (ADME) characteristics. Tests in mice and rats revealed high oral bioavailability alongside preferential drug enrichment in lung tissues.
In Vivo Testing in Animal Models
To assess therapeutic impact in living systems, researchers utilized K18-hACE2 mice infected with human SARS-CoV-2. According to company-reported findings, repeated oral dosing of the PLpro inhibitor produced dose-dependent reductions in pulmonary viral replication. Sunshine Biopharma focuses its pharmaceutical pipeline on oncology and antiviral therapies, developing small-molecule drug candidates for serious diseases. The coronavirus PLpro inhibitor program remains in the preclinical phase as the organization prepares its regulatory submissions and evaluates timelines for future clinical development.
